We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Neuronal Identity Established by Specific Transcription Factors

By LabMedica International staff writers
Posted on 21 May 2018
Print article
Image: Human induced neurons generated from a novel transcription factor pair. Colors represent a nuclear stain (DAPI) in blue, synaptic marker expression (Synapsin1) in green, and neuron-specific beta-III tubulin expression (Tuj1) in red (Photo courtesy of Dr. Kristin Baldwin, The Scripps Research Institute).
Image: Human induced neurons generated from a novel transcription factor pair. Colors represent a nuclear stain (DAPI) in blue, synaptic marker expression (Synapsin1) in green, and neuron-specific beta-III tubulin expression (Tuj1) in red (Photo courtesy of Dr. Kristin Baldwin, The Scripps Research Institute).
A team of neurodegenerative disease researchers has developed a protocol for the consistent transformation of stem cells of fibroblast origin into specific classes of neurons for brain research and drug development.

Transient expression of certain transcription factors has been found to endow non-neural cells with neuronal properties. The relationship between reprogramming factors and the transcriptional networks that produce neuronal identity and diversity remains largely unknown.

To study this process, investigators at The Scripps Research Institute (La Jolla, CA; USA) screened 598 pairs of transcription factors in a mouse model system.

They reported in the May 9, 2018, online edition of the journal Nature that 76 pairs of transcription factors (12.7%) induced mouse fibroblasts to differentiate into cells with neuronal features. By comparing the transcriptomes of these induced neuronal cells (iN cells) with those of natural neurons, the investigators defined a "core" cell-autonomous neuronal signature. The iN cells also exhibited diversity; each transcription factor pair produced iN cells with unique transcriptional patterns that could predict their pharmacological responses. By linking distinct transcription factor input "codes" to defined transcriptional outputs, these findings delineated cell-autonomous features of neuronal identity and diversity and expanded the reprogramming toolbox to facilitate engineering of induced neurons with desired patterns of gene expression and related functional properties.

"The brain is incredibly complex, with thousands of different types of cells that are each involved in different diseases," said senior author Dr. Kristin Baldwin, a professor at the Scripps Research Institute. "The problem with understanding and treating the many disorders of the brain is that we cannot reproducibly produce the right types of brain cells. Now we have found more than 75 new ways to rapidly and reproducibly turn skin cells into neurons that we think will be much better representatives of different neurologic diseases than were previously available. Having a personalized and nearly unlimited supply of different types of neuronal cells in a dish lets you uncover what is going wrong in a disease. At the same time, the study supplies a new toolkit to test thousands of drugs on the affected cells to try to reverse the problems, rather than having to test them in mice or other animals, with results that are often difficult to interpret for human conditions."

Related Links:
The Scripps Research Institute

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.